InflaRx (IFRX) hit with Nasdaq minimum $1 bid-price warning and cure window

Rhea-AI Filing Summary

InflaRx N.V. reports it has received a Nasdaq notice that its ordinary shares no longer meet the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The bid price has been below this threshold for thirty consecutive business days.

The company has 180 calendar days, until September 7, 2026, to regain compliance, and may seek a transfer to the Nasdaq Capital Market, which could provide an additional 180 days, until March 8, 2027. The notice does not immediately affect listing or trading, and InflaRx plans to monitor its share price and consider options to restore compliance.

Positive

• None.

Negative

• Nasdaq minimum bid-price deficiency: InflaRx’s ordinary shares traded below the $1.00 minimum for thirty consecutive business days, triggering a Nasdaq notice and starting a cure period, which introduces the risk of potential delisting or market transfer if compliance is not regained.

Insights

Equity and listing compliance analyst

Nasdaq bid-price deficiency introduces listing risk but allows up to 360 days for remediation.

InflaRx has fallen out of compliance with Nasdaq’s $1.00 minimum bid price rule after thirty consecutive business days below the threshold. Under Nasdaq rules, the company has an initial 180-day cure period ending on September 7, 2026.

If it does not regain compliance by then, InflaRx may apply to move from the Nasdaq Global Select Market to the Nasdaq Capital Market, potentially gaining another 180 days to March 8, 2027, subject to meeting other listing standards and Nasdaq approval. The notice currently has no effect on trading, but introduces visible listing risk.

Actual impact will depend on the company’s ability to lift its share price back above $1.00 for the required period and, if needed, on Nasdaq’s decision regarding any requested market transfer and extended compliance window.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private

Issuer Pursuant to Rule

13a-16 or 15d-16 under the

Securities Exchange Act

of 1934

For the month of March 2026

Commission File

Number: 001-38283

InflaRx N.V.

Winzerlaer Str. 2

07745 Jena,

Germany

(+49) 3641508180

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F  ☐

EXPLANATORY NOTE

On March 13, 2026, InflaRx N.V. (the “Company”) issued a press release announcing that it had received a written notice (the “Notice”), dated as of March 11, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s ordinary shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial period of 180 calendar days, or until September 7, 2026, to regain compliance. If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement). Such transfer would provide the Company with an additional 180 calendar days, or until March 8, 2027, to regain compliance. There can be no assurance that the Company would be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company’s request for continued listing.

The Notice has no immediate effect on the listing or trading of the Company’s ordinary shares.

The Company intends to monitor the bid price of its ordinary shares and consider available options to regain compliance with the Minimum Bid Price Rule.

This report on Form 6-K (the “Report”) shall be deemed to be incorporated by reference into (i) the registration statements on Form S-8 (File No. 333-221656 and 333-240185) and (ii) the registration statement on Form F-3 (File No. 333-273058) of the Company and to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

A copy of the press release is attached as Exhibit 99.1 to this Report. Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

FORWARD-LOOKING STATEMENTS

This Report contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others, statements regarding our compliance with the Minimum Bid Price Rule and listing or trading of our ordinary shares. Forward-looking statements appear in a number of places throughout this Report and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements,” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release, dated March 13, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INFLARX N.V.
Date: March 13, 2026	By:	/s/ Niels Riedemann
	Name:	Niels Riedemann
	Title:	Chief Executive Officer

Exhibit 99.1

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Jena, Germany, March 13, 2026 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated March 11, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s ordinary shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until September 7, 2026, to regain compliance. If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement). Such transfer would provide the Company with an additional 180 calendar days, or until March 8, 2027, to regain compliance. There can be no assurance that the Company would be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company’s request for continued listing.

The Notice has no immediate effect on the listing or trading of the Company’s ordinary shares. The Company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule.

About InflaRx N.V.

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS). The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others, statements regarding our compliance with the Minimum Bid Price Rule and listing or trading of our ordinary shares. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

What Nasdaq notice did InflaRx (IFRX) receive in March 2026?

InflaRx received a Nasdaq deficiency notice stating its ordinary shares failed to meet the $1.00 minimum bid price for thirty consecutive business days. This triggers a cure period under Nasdaq Listing Rule 5810(c)(3)(A) to restore compliance and protect its current listing status.

How long does InflaRx (IFRX) have to regain Nasdaq minimum bid price compliance?

InflaRx has an initial 180-day period, until September 7, 2026, to regain compliance with Nasdaq’s $1.00 minimum bid price rule. If unsuccessful, and if it meets other criteria, a transfer to the Nasdaq Capital Market could extend this by another 180 days.

Does the Nasdaq deficiency notice immediately affect trading of InflaRx (IFRX) shares?

The notice has no immediate effect on the listing or trading of InflaRx’s ordinary shares. The company continues to trade on the Nasdaq Global Select Market while it attempts to restore compliance with the minimum bid price requirement during the allowed cure periods.

What additional time could InflaRx (IFRX) get by moving to the Nasdaq Capital Market?

If InflaRx does not regain compliance by September 7, 2026, it may apply to transfer to the Nasdaq Capital Market. If Nasdaq approves and other listing conditions are met, this transfer could provide an additional 180 calendar days, until March 8, 2027, to regain compliance.

What options is InflaRx (IFRX) considering to regain Nasdaq bid price compliance?

InflaRx states it intends to monitor the bid price of its ordinary shares and consider available options to regain compliance with Nasdaq’s Minimum Bid Price Rule. Specific measures are not detailed, but the company emphasizes its focus on meeting the listing standard.

What is the key Nasdaq rule affecting InflaRx (IFRX) in this notice?

The notice references Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share for continued listing on the Nasdaq Global Select Market. The cure period mechanics are governed by Nasdaq Listing Rule 5810(c)(3)(A).

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 9.3 KB